Tight glycemic control and cardiovascular effects in type 2 diabetic patients

Latha Subramanya Moodahadu; Ruchi Dhall; Abdul Hamid Zarġar; Sudhakar Banġera; Lalitha Ramani; Ramesh Katipally

doi:10.4103/1995-705X.151084

		Login \| Users Online: 348
Home \| About us \| Editorial board \| Search \| Ahead of print \| Current Issue \| Archives \| Submit article \| Instructions \| Subscribe \| Advertise \| Contact us

REVIEW ARTICLE

Year : 2014 | Volume : 15 | Issue : 4 | Page : 111-120

Tight glycemic control and cardiovascular effects in type 2 diabetic patients

Latha Subramanya Moodahadu¹, Ruchi Dhall², Abdul Hamid Zarġar³, Sudhakar Banġera⁴, Lalitha Ramani⁵, Ramesh Katipally¹
¹ Dr. Reddy's Laboratories Ltd., Hyderabad Telangana, India
² Consultant Physician, Ahmedabad, Gujarat, India
³ Member Institute Body, AIIMS and Endocrinologist, Advanced Center for Diabetes and Endocrine Care, Srinagar, Jammu and Kashmir, India
⁴ Program Director, Clinical Development Service Agency, Gurgaon, India
⁵ General Practitioner and Family Physician, Hyderabad, Telangana, India

Correspondence Address:
Dr. Latha Subramanya Moodahadu
G 5, Mount Meru Apartment, Road 5, Avenue 7, Banjara Hills, Hyderabad 500 034, Andhra Pradesh
India

Source of Support: None, Conflict of Interest: Dr Latha, Manager, Global Medical Affairs, Dr Reddy's Laboratories Ltd., Hyderabad. Ramesh Katipally, Group Product Manager, Dr Reddy's Laboratories Ltd

Check

DOI: 10.4103/1995-705X.151084

Diabetes Mellitus (DM) with poor glycemic control is one of the leading causes for cardiovascular mortality in diabetic patients. Tight glycemic control with glycosylated haemoglobin of <7 gms% is recommended as a routine and < 6.5 gms% is recommended for young and newly diagnosed diabetics. Treatment goal aims at achieving near normal blood glucose level, and directed at management of other co morbid conditions such as obesity, hypertension and dyslipidemia. Oral hypoglycemic agents are the preferred drugs, alone or in combination. Preference for glitazones is declining due to the increasing evidences of associated adverse events. Gliptins appear as promising agents with lesser tendency to cause hypoglycemia, but their long term safety and efficacy is yet to be established. We emphasize the role of preventive measures in prediabetics and in established DM, treatment should be individualized and customized to minimize hypoglycemic effects and to retain quality of life.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	8172

Printed	120

Emailed	0

PDF Downloaded	239

Comments	[Add]

Cited by others	12